Radiology Partners, Inc., a Delaware corporation (the “Company”), today announced that it has commenced a solicitation of consents (“Consents” and such solicitation the “Consent Solicitation”) from the noteholders (each, a “Noteholder”) of the Company’s Second Lien Senior Secured PIK Notes due 2030 (the “Notes”) to adopt certain proposed amendments (the “Proposed Amendments”) to the indenture governing the Notes (the “Indenture”) to facilitate the consummation of the previously announced acquisition of Everlight Radiology Holdings Pty Ltd (the “Everlight Acquisition”).

The Consent Solicitation will expire at 5:00 P.M., New York City time, on October 9, 2026 or such later time and date to which such Consent Solicitation may be extended or earlier terminated (such time and date, the “Expiration Time”). Noteholders must deliver, and not revoke, valid Consents prior to the Expiration Time to be eligible to receive the Consent Fee (as defined below). Consents may be revoked at any time prior to the “Consent Date” which is the earlier of (a) the Effective Date (as defined in the Consent Solicitation Statement) for the Consent Solicitation and (b) 5:00 P.M., New York City time, on October 9, 2026 or such later time and date to which such date may be extended. The Consent Solicitation is subject to the satisfaction or waiver (as applicable) of certain conditions set forth in the consent solicitation statement, dated October 5, 2026 (the “Consent Solicitation Statement”).

The Consents of the Noteholders of at least a majority in aggregate principal amount of all the outstanding Notes are required pursuant to the terms of the Indenture for the Proposed Amendments to be approved and binding on all of the Noteholders and any subsequent Noteholder (the “Requisite Consents”). As of the date hereof, Noteholders holding approximately 60% of the aggregate principal amount of the outstanding Notes, which would exceed the Requisite Consents, have entered into a support agreement with the Company (the “Support Agreement”) pursuant to which they have committed to participate in the Consent Solicitation and provide their Consent to the Proposed Amendments prior to the Expiration Time. Therefore, the Company expects to receive the necessary Consents to adopt the Proposed Amendments prior to the Expiration Time.

Consents may be delivered in minimum denominations of $1.00 and integral multiples of $1.00 in excess thereof. The Company is offering each Noteholder that validly grants (and does not validly revoke) a Consent prior to the Expiration Time and whose Consent the Company accepts (each such Noteholder, a “Consenting Holder” and the Notes held by such Consenting Holders and validly submitted for consents in this Consent Solicitation (and not validly revoked), collectively, the “Consenting Notes”) consideration equal to a pro rata portion of 2.0% of the aggregate principal amount of outstanding Notes as of the date of the Consent Solicitation Statement (the “Consent Fee”). The payment of the Consent Fee is conditioned upon satisfaction or waiver (as applicable) of certain conditions set out in the Consent Solicitation Statement, including obtaining the Requisite Consents and the consummation of the Everlight Acquisition. The Consent Fee is expected to be paid in cash only to Consenting Holders in this Consent Solicitation substantially concurrently with the consummation of the Everlight Acquisition. No Consent Fee shall be paid if the Everlight Acquisition does not occur.

Pursuant to the Support Agreement, the Company is also required to commence an offer to purchase only Consenting Notes for cash (the “Future Tender Offer”) within ten (10) business days following the closing date of the Everlight Acquisition, in an aggregate amount equal to 8% of the aggregate principal amount of Notes outstanding (subject to the Additional Repurchase Amount (as defined in the Consent Solicitation Statement) as of (i) the early expiration time of the Future Tender Offer or (ii) to the extent no early expiration time exists, the expiration time of the Future Tender Offer (any of (i) or (ii), as the case may be, the “Future Tender Offer Expiration Time”) (which shall include any increase in principal amount resulting from any PIK Payment (as defined in the Indenture) made on or prior to the Future Tender Offer Expiration Time) (the “Repurchase Amount”) at a price of 100% of the aggregate principal amount of such Notes, plus accrued and unpaid interest, in each case, to be set forth in the offer to purchase related to this tender offer. The Repurchase Amount is subject to automatic increase by the Additional Repurchase Amount for each thirty (30)-day period following the closing date of the Everlight Acquisition during which the Future Tender Offer is not completed, as further described in the Consent Solicitation Statement.

The Consent Solicitation is being made to all holders of Notes held through The Depository Trust Company (“DTC”) by participants in DTC (“DTC Participants”). A beneficial owner of an interest in a Note (“Beneficial Owner”) held through a DTC Participant must properly instruct such DTC Participant to cause a Consent to be given by such DTC Participant with respect to such Note. Consents must be electronically delivered in accordance with DTC’s Automated Tender Offer Program procedures. Beneficial Owners whose Notes are held through a broker, dealer, commercial bank, trust company or other nominee should note that their nominee may establish a deadline earlier than the Consent Date by which instructions must be received by them in relation to the Consent Solicitation and, accordingly, Beneficial Owners are urged to contact their nominees as soon as possible to learn of any deadlines established by their nominees in relation to the Consent Solicitation.

The Company expressly reserves the right, at any time prior to the Effective Date, to amend any of the terms of the Consent Solicitation in any manner it deems necessary or advisable in its sole discretion, in accordance with applicable law and its contractual obligations. The Consent Solicitation may be terminated at any time prior to, or after, the Expiration Time and prior to the Effective Date, in the Company’s sole discretion, whether or not the Requisite Consents have been received.

The Company has appointed Global Bondholder Services Corporation as tabulation agent (the “Tabulation Agent”) for Consents with respect to the Consent Solicitation and as information agent (the “Information Agent”) with respect to the Consent Solicitation Statement. The Company has appointed Barclays Capital Inc. as solicitation agent with respect to the Consent Solicitation (the “Solicitation Agent”). Wilmington Trust, National Association, as Trustee and Notes Collateral Agent, is not involved in the Consent Solicitation and has no responsibility relating to such Consent Solicitation. The contact information for the Tabulation Agent, the Information Agent and the Solicitation Agent is set forth below.

Noteholders are urged to carefully read the entire Consent Solicitation Statement, including the information presented under “Certain Risk Factors Relating to the Consent Solicitation” and “Statement Regarding Forward-Looking Statements” before making any decision with respect to the Consent Solicitation. None of the Company, the Solicitation Agent, the Trustee, the Notes Collateral Agent, the Information Agent or the Tabulation Agent makes any recommendation as to whether or not Noteholders should deliver Consents in response to the Consent Solicitation. Each Noteholder must make its own decision as to whether or not to deliver a Consent.

About Radiology Partners

Radiology Partners, Inc., through RP Clinical Services and its managed practices, together with Mosaic Clinical Technologies, Inc., its technology and AI division, is the leading provider of technology-enabled radiology services in the U.S., serving more than 3,400 hospitals and other healthcare facilities with high-quality radiology, technology and artificial intelligence solutions. As a physician-led and physician-owned practice, our mission is to transform radiology by innovating across clinical value, technology, and service, while elevating the role of radiology and radiologists in healthcare.

No Offer or Solicitation

This press release is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote, consent or approval in any jurisdiction in connection with the Consent Solicitation, or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. In particular, this communication is not an offer of securities for sale into the United States. No offer of securities shall be made in the United States absent registration under the Securities Act or pursuant to an exemption from, or in a transaction not subject to, such registration requirements.

Cautionary Note Regarding Forward-Looking Statements

Certain statements made herein may be deemed “forward-looking statements” within the meaning of federal securities laws, including any statements regarding the consummation of the Consent Solicitation. Any statements that are not statements of historical fact should be considered forward-looking statements. In many cases, forward-looking statements can generally be identified by the use of forward-looking terminology such as “may,” “plan,” “predict,” “expect,” “estimate,” “intend,” “would,” “will,” “could,” “should,” “anticipate,” “believe,” “project” or “continue” or the negative thereof or other similar expressions. All forward-looking statements speak only as of the date of this press release. Although the Company believes that its plans, intentions and expectations reflected in or suggested by the forward-looking statements are reasonable, such plans, intentions or expectations may not be achieved. The Company cautions Noteholders that any forward-looking statements are subject to risks and uncertainties, including risks in connection with the timing of the consummation of the Everlight Acquisition, our ability to satisfy closing conditions for the Everlight Acquisition and anticipated benefits flowing from the Everlight Acquisition, any of which may cause actual results and future trends to differ materially from those projected, stated or implied by the forward-looking statements. In addition, the Company encourages Noteholders to read the risks and uncertainties under the heading “Risk Factors” in the Company’s annual report and the heading “Certain Risk Factors Relating to the Consent Solicitation” in the Consent Solicitation Statement. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Questions and requests for assistance or additional copies of the Consent Solicitation Statement and the Indenture may be directed to the Information Agent at the address below. Noteholders should retain their Notes and not deliver any such Notes to the Tabulation Agent or the Information Agent. Duly executed Consents should be delivered through DTC, as described in the Consent Solicitation Statement:

Global Bondholder Services Corporation

65 Broadway, Suite 404

New York, New York 10006

Banks and Brokers Call Collect: (212) 430-3774

All Others Call Toll-Free: (855) 654-2015

Email: contact@gbsc-usa.com with reference to “Radiology Partners” in the subject line

A Noteholder may also contact such Noteholder’s broker, dealer, commercial bank, trust company or other nominee for assistance concerning the Consent Solicitation.

Questions concerning the terms of this Consent Solicitation should be directed to the Solicitation Agent:

Barclays Capital Inc.

745 Seventh Avenue, 5th Floor

New York, NY 10019

Collect: (212) 528-7581

Email: us.lm@barclays.com

Attention: Liability Management Group

Media gallery

About The Author
Business Wire